Advertisement

EP News: Pediatric and Congenital Electrophysiology

  • Vicki A. Freedenberg
    Correspondence
    Address reprint requests and correspondence: Dr Vicki A. Freedenberg, Division of Cardiology, Children’s National Hospital, 111 Michigan Avenue NW, Washington, DC 20010.
    Affiliations
    Division of Cardiology, Children’s National Hospital, Washington, District of Columbia
    Search for articles by this author
Published:November 07, 2021DOI:https://doi.org/10.1016/j.hrthm.2021.11.005
      Ho et al (Nat Med 2021;27:1818, PMID 34556856) conducted a multicenter, double-blind, placebo-controlled, phase 2 clinical trial to assess the safety and efficacy of angiotensin II receptor blocker valsartan in attenuating disease evolution in early hypertrophic cardiomyopathy (HCM). In total, 178 participants with early-stage sarcomeric HCM were randomized (1:1) to receive valsartan or placebo for 2 years. Standardized changes from baseline to year 2 in left ventricular wall thickness, mass, and volumes; left atrial volume; tissue Doppler diastolic and systolic velocities; and serum levels of high-sensitivity troponin T and N-terminal pro-B-type natriuretic protein were integrated into a single composite z score as the primary outcome. Valsartan (n = 88) improved cardiac structure and function compared with placebo (n = 90), as reflected by an increase in the composite z score (between-group difference 0.231; 95% confidence interval 0.098–0.364; P = .001), which met the primary end point of the study. Treatment was well-tolerated. The authors conclude that these results suggest an important opportunity to attenuate disease progression in early-stage sarcomeric HCM with a widely available and safe pharmacological intervention.
      To read this article in full you will need to make a payment
      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect